FebriDx® Test Featured in UK National Institute for Health and Care Excellence

Business

SRQ DAILY WEDNESDAY PHILANTHROPY EDITION WEDNESDAY SEP 9, 2020

Lumos Diagnostics today announced its rapid point-of-care (POC) diagnostic test FebriDx® was featured in a Medtech Innovation Briefing (MIB), as part of the United Kingdom’s National Institute for Health and Care Excellence (NICE) guidance for the COVID-19 pandemic response. This MIB addresses the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises. “As hospitals and clinics continue to struggle with capacity and patient care during the COVID-19 pandemic, the ability to facilitate prompt and accurate testing is the key to not only better patient care but also an accelerated recovery. FebriDx offers rapid results, which helps clinicians make accurate triage and treatment decisions,” said Robert Sambursky, MD, president and chief executive officer for Lumos Diagnostics. “As the UK continues to work to control the COVID-19 pandemic, the FebriDx MIB will give clinicians critical diagnostic information to improve patient care and therapeutic outcomes, while also protecting their healthcare facilities and communities across the UK.”

Click here for more information.

« View The Wednesday Sep 9, 2020 SRQ Daily Edition
« Back To SRQ Daily Archive

Read More

Don't Miss SRQ Magazine's January 2021 Health and Wellness Edition

Don't Miss SRQ Magazine's January 2021 Health and Wellness Edition

Jan 19, 2021

Integrative Skin Care Opens in Sarasota

Integrative Skin Care Opens in Sarasota

Jan 14, 2021

ROBRADY-Designed Shields Contain Air Contaminants

ROBRADY-Designed Shields Contain Air Contaminants

Jacob Ogles | Jan 11, 2021

Paying Wellness Forward

Paying Wellness Forward

Abby Weingarten | Jan 6, 2021